Physician profile
Lisa Feulner
NPI 1063401362
$434,261.46
in general payments reported to CMS, 2019-2025
38 companies · $115K in 2025
The $115K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83K · 2020: $44K · 2021: $34K · 2022: $81K · 2023: $51K · 2024: $26K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $125K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Travel and Lodging: $14K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $125,076.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,970.00 |
| Travel and Lodging | $14,468.93 |
| Food and Beverage | $11,540.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $89,721.00 | 2022-2025 | Envista Mx60 Iol, Crystalens Accommodating Iol (At-52ao), Stellaris Elite |
| Sun Pharmaceutical Industries INC. | $70,293.58 | 2019-2025 | Cequa |
| Alcon Vision LLC | $49,556.37 | 2019-2025 | Tryptyr, Hydrus Microstent, Rocklatan |
| Allergan, INC. | $42,144.49 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $31,895.41 | 2019-2023 | |
| Glaukos Corporation | $29,462.71 | 2023-2025 | Travoprost Intraocular Implant - Idose, Idosetr, Idose |
| Kala Pharmaceuticals, INC. | $27,594.52 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $23,370.05 | 2019-2025 | Iolmaster 700, Veracity Surgical, Artevo 800 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16,112.96 | 2019-2021 | |
| Shire North American Group INC | $14,928.31 | 2019 | |
| Abbvie INC. | $10,882.06 | 2022-2025 | |
| Thea Pharma INC. | $6,405.64 | 2022-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $4,964.52 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $3,668.50 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $3,647.47 | 2022-2025 | Veracity Surgical, Cataract Suite, Quatera 700 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $3,030.02 | 2019-2024 | Tecnis Iol, Catalys System, Tecnis Iol |
| Harrow Eye, LLC | $1,566.62 | 2024-2025 | Vevye, Iheezo, Triesence |
| Oyster Point Pharma, INC. | $1,554.27 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $941.47 | 2019-2025 | Omni Surgical System, Tearcare System, Sion Surgical Instrument |
| Tarsus Pharmaceuticals, INC. | $764.09 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $652.00 | 2019-2025 | Oxervate |
| Ivantis, INC | $196.56 | 2019-2021 | |
| Amgen INC. | $122.94 | 2024-2025 | Tepezza |
| Quidel Corporation | $108.93 | 2023 | |
| Biotissue Holdings INC. | $107.80 | 2022-2025 | |
| Notal Vision, INC. | $104.15 | 2019 | |
| Mallinckrodt Hospital Products INC. | $82.28 | 2021-2025 | Acthar |
| Apellis Pharmaceuticals, INC. | $58.01 | 2023-2024 | Syfovre |
| Rxsight INC | $56.65 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Rayner Intraocular Lenses Limited | $56.55 | 2023-2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Aerie Pharmaceuticals, INC. | $46.56 | 2019-2021 | |
| Ortho-Clinical Diagnostics, INC. | $45.99 | 2024 | Inflammadry |
| Astellas Pharma US INC | $33.33 | 2023 | |
| Merz Pharmaceuticals, LLC | $21.74 | 2023 | Xeomin |
| Lensar, INC. | $18.95 | 2024 | Lensar Laser System |
| Horizon Therapeutics Plc | $17.54 | 2021 | |
| Galderma Laboratories, L.P. | $16.10 | 2023 | Dysport |
| Johnson & Johnson Vision Care, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Feulner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.